Yeo lab:Projects: Difference between revisions
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
|style="background:#ffffff"| | |style="background:#ffffff"| | ||
One of the major obstacles in translating potent drug candidates from bench to bedside is their spatiotemporally adequate delivery. For example, small interfering RNA (siRNA) has been recognized as a promising new class of drugs for viral infections, neurodegenerative diseases, and cancer; however, its therapeutic potential has not been realized because of the instability in circulation and inefficient delivery to the target cells. Target-specific delivery of anti-cancer drugs with minimal side effects on normal tissues has long been a goal for cancer therapy, but their clinical application remains challenging. | |||
We are interested in developing drug/gene delivery systems which can address these challenges in ‘delivery.’ Research projects will focus on i) addressing the obstacles in siRNA delivery using formulation approaches, (ii) developing nanoparticles which mimic leukocyte-rolling behavior for tumor targeting, and (iii) developing inhalable microparticles which allows for delivering combinations of drugs for cystic fibrosis therapy. | |||
Under construction... more to come... | |||
|}<br style="clear:both" /> | |}<br style="clear:both" /> | ||
Revision as of 23:49, 13 January 2007
|
One of the major obstacles in translating potent drug candidates from bench to bedside is their spatiotemporally adequate delivery. For example, small interfering RNA (siRNA) has been recognized as a promising new class of drugs for viral infections, neurodegenerative diseases, and cancer; however, its therapeutic potential has not been realized because of the instability in circulation and inefficient delivery to the target cells. Target-specific delivery of anti-cancer drugs with minimal side effects on normal tissues has long been a goal for cancer therapy, but their clinical application remains challenging. We are interested in developing drug/gene delivery systems which can address these challenges in ‘delivery.’ Research projects will focus on i) addressing the obstacles in siRNA delivery using formulation approaches, (ii) developing nanoparticles which mimic leukocyte-rolling behavior for tumor targeting, and (iii) developing inhalable microparticles which allows for delivering combinations of drugs for cystic fibrosis therapy. Under construction... more to come... |
